Finanzen von Milestone Scientific Inc (MLSS)MLSSMilestone Scientific Inc

Milestone Scientific Inc (MLSS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Handpieces, accounting for 56.6% of total sales, equivalent to $1.61M. Other significant revenue streams include Instruments and Accessories. Understanding this composition is critical for investors evaluating how MLSS navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Milestone Scientific Inc maintains a gross margin of 66.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -37.37%, while the net margin is -37.29%. These profitability ratios, combined with a Return on Equity (ROE) of -121.67%, provide a clear picture of how effectively MLSS converts its operational activities into shareholder value.

In the context of the broader market, MLSS competes directly with industry leaders such as BDMD and POCI. With a market capitalization of $47.87M, it holds a significant position in the sector. When comparing efficiency, MLSS's gross margin of 66.55% stands against BDMD's 83.79% and POCI's 23.61%. Such benchmarking helps identify whether Milestone Scientific Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 66.55% in Q2 2026, which is a decline from previous quarters, indicating potential profitability challenges. However, total revenue for Q2 2026 was $2.8 million, reflecting a 22% year-over-year increase.